REGULATORY INTELLIGENCE·USFDA
Aurobindo Pharma Unit VII: FDA Issues Warning Letter Citing Data Integrity Failures Across Three API Lines
Inspection reveals repeated data integrity violations in analytical testing, resulting in OAI classification and an import alert that detains shipments without physical examination pending remediation.
90-Day Activity